Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Laekna, Inc. ( (HK:2105) ) has shared an update.
Laekna, Inc. announced the successful completion of a placement of 36,000,000 new shares under a general mandate, raising funds to strengthen its financial position for future development. The proceeds will support the company’s ongoing R&D activities, including the advancement of its ActRII portfolio and other pipeline products, as well as improving production capacities and business development activities.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$26.45 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a science-driven, clinical-stage biotechnology company focused on the research and development of novel therapies. The company requires substantial cash flow to support its ongoing R&D activities, particularly for its ActRII portfolio, including LAE102, LAE103, and LAE123, as well as other pipeline products.
Average Trading Volume: 4,636,521
Technical Sentiment Signal: Hold
See more data about 2105 stock on TipRanks’ Stock Analysis page.